Characteristics | Training cohort (n = 226) | Testing cohort (n = 98) | ||||
---|---|---|---|---|---|---|
Benign (n = 116) | Malignant (n = 110) | p | Benign (n = 50) | Malignant (n = 48) | p | |
Gender | Â | Â | 0.319 | Â | Â | 0.658 |
 Female | 76 (65.5%) | 65 (59.1%) |  | 28 (56.0%) | 29 (60.4%) |  |
 Male | 40 (34.5%) | 45 (40.9%) |  | 22 (44.0%) | 19 (39.6%) |  |
Age (years) | 56.4 ± 10.7 | 55.6 ± 9.5 | 0.572 | 56.7 ± 9.1 | 55.8 ± 9.8 | 0.629 |
Smoking history | Â | 0.981 | Â | Â | 0.307 | |
 Yes | 22 (19.0%) | 21 (19.1%) |  | 12 (24.0%) | 16 (33.3%) |  |
 No | 94 (81.0%) | 89 (80.9%) |  | 38 (76.0%) | 32 (66.7%) |  |
Diameter (mm) | 6.7 ± 1.9 | 8.4 ± 1.5 |  < 0.001 | 6.5 ± 1.8 | 7.9 ± 1.7 |  < 0.001 |
Location | Â | Â | 0.281 | Â | Â | 0.857 |
 RUL | 23 (19.8%) | 22 (20.0%) |  | 7 (14.0%) | 7 (14.6%) |  |
 RML | 19 (16.4%) | 9 (8.2%) |  | 10 (20.0%) | 7 (14.6%) |  |
 RLL | 26 (22.4%) | 24 (21.8%) |  | 16 (32.0%) | 13 (27.1%) |  |
 LUL | 17 (14.7%) | 25 (22.7%) |  | 8 (16.0%) | 11 (22.9%) |  |
 LLL | 31 (26.7%) | 30 (27.3%) |  | 9 (18.0%) | 10 (20.8%) |  |
Enhancement degree | Â | 0.477 | Â | Â | 0.864 | |
 Low | 91 (78.4%) | 93 (84.5%) |  | 43 (86.0%) | 41 (85.4%) |  |
 Medium | 13 (11.2%) | 8 (7.3%) |  | 3 (6.0%) | 4 (8.3%) |  |
 High | 12 (10.3%) | 9 (8.2%) |  | 4 (8.0%) | 3 (6.2%) |  |
Nodule-lung interface |  |  < 0.001 |  |  | 0.003 | |
 Clear | 111 (95.7%) | 84 (76.4%) |  | 48 (96.0%) | 36 (75.0%) |  |
 Blurred/Halo | 5 (4.3%) | 26 (23.6%) |  | 2 (4.0%) | 12 (25.0%) |  |
Lobulation | 72 (62.1%) | 93 (84.5%) |  < 0.001 | 22 (44.0%) | 41 (85.4%) |  < 0.001 |
Spiculation | 6 (5.2%) | 49 (44.5%) |  < 0.001 | 4 (8.0%) | 17 (35.4%) | 0.001 |
Vacuole | 2 (1.7%) | 22 (20.0%) |  < 0.001 | 1 (2.0%) | 4 (8.3%) | 0.334 |
Pleural indentation 17 (14.7%) | 54 (49.1%) |  < 0.001 | 6 (12.0%) | 20 (41.7%) | 0.001 | |
Air bronchogram 1 (0.9%) | 23 (20.9%) |  < 0.001 | 1 (2.0%) | 11 (22.9%) | 0.002 | |
Vascular convergence 0 (0.0%) | 6 (5.5%) | 0.033 | 0 (0.0%) | 5 (10.4%) | 0.060 |